Target Validation Information
Target ID T52450
Target Name Interstitial collagenase
Target Type
Successful
Drug Potency against Target Ro-37-9790 Drug Info IC50 = 4.9 nM
Marimastat Drug Info IC50 = 5 nM [552497]
4-Butoxy-N-hydroxycarbamoylmethyl-benzamide Drug Info IC50 = 920 nM [527800]
CIPEMASTAT Drug Info Ki = 0.3 nM [528065]
4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol Drug Info IC50 = 8000 nM [525485]
3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol Drug Info IC50 = 1500 nM [525485]
N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3 Drug Info Ki = 900 nM [531455]
BMS 275291 Drug Info Ki = 9 nM [537564]
3-Benzenesulfonyl-heptanoic acid hydroxyamide Drug Info IC50 = 300 nM [525813]
PKF-242-484 Drug Info Ki = 1 nM [528065]
3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol Drug Info IC50 = 1000 nM [525535]
N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide Drug Info Ki = 33 nM [527800]
L-696418 Drug Info Ki = 760 nM
Prinomastat Drug Info Ki = 8.3 nM
BB-3644 Drug Info IC50 = 10 nM [552497]
ILOMASTAT Drug Info IC50 = 0.4 nM [529683]
TMI-05 Drug Info IC50 = 33 nM [527982]
4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide Drug Info IC50 = 920 nM [527800]
RS-39066 Drug Info IC50 = 6.9 nM
3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol Drug Info IC50 = 1700 nM [525535]
3-Benzenesulfinyl-heptanoic acid hydroxyamide Drug Info IC50 = 93 nM [525813]
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide Drug Info IC50 = 54 nM [525813]
Ro-31-4724 Drug Info IC50 = 40 nM [527073]
SR-973 Drug Info Ki = 21 nM [528025]
CIPEMASTAT Drug Info IC50 = 7 nM
MMI270 Drug Info IC50 = 33 nM [527922]
N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide Drug Info IC50 = 22 nM [527800]
3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol Drug Info IC50 = 1500 nM [525485]
3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol Drug Info IC50 = 600 nM [525485]
N-Hydroxycarbamoylmethyl-4-methoxy-benzamide Drug Info Ki = 33 nM [527800]
N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide Drug Info IC50 = 22 nM [527800]
BB-1101 Drug Info IC50 = 2.2 nM [534793]
SC-44463 Drug Info IC50 = 20 nM [526680]
RS-130830 Drug Info Ki = 590 nM [527412]
RO-319790 Drug Info IC50 = 5 nM [534791]
Action against Disease Model XL784 Both a MMP-1 inhibitor and P1pal-7 significantly promote apoptosis in breast t uMor xenografts and inhibit metastasis to the lungs by up to 88%. Biochemical analysis of xenograft t uMors treated with P1pal-7 or MMP-1 inhibitor showed attenuated Akt activity [552963] Drug Info
The Effect of Target Knockout, Knockdown or Genetic Variations Spontaneous retarded lung alveolar development and diminished surface area; Impaired osteocyte processes and collagen cleavage
References
Ref 552497Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des. 2005;11(3):295-322.
Ref 552963Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 2009 Aug 1;69(15):6223-31. doi: 10.1158/0008-5472.CAN-09-0187. Epub 2009 Jul 21.
Ref 527800J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking.
Ref 528065Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6. Epub 2006 Mar 3.A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.
Ref 525485Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.
Ref 525485Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.
Ref 531455J Med Chem. 1990 Jan;33(1):263-73.Phosphoramidate peptide inhibitors of human skin fibroblast collagenase.
Ref 537564Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
Ref 525813J Med Chem. 2000 Jun 15;43(12):2324-31.Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
Ref 528065Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6. Epub 2006 Mar 3.A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.
Ref 525535Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.Synthesis and identification of conformationally constrained selective MMP inhibitors.
Ref 527800J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking.
Ref 552497Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des. 2005;11(3):295-322.
Ref 529683Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. Epub 2008 Jul 20.Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
Ref 527982Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. Epub 2006 Jan 19.Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Ref 527800J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking.
Ref 525535Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.Synthesis and identification of conformationally constrained selective MMP inhibitors.
Ref 525813J Med Chem. 2000 Jun 15;43(12):2324-31.Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
Ref 525813J Med Chem. 2000 Jun 15;43(12):2324-31.Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
Ref 527073J Med Chem. 2004 May 20;47(11):2761-7.Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase.
Ref 528025Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. Epub 2006 Feb 10.Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
Ref 527922Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. Epub 2005 Dec 9.The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Ref 527800J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking.
Ref 525485Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.
Ref 525485Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.
Ref 527800J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking.
Ref 527800J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking.
Ref 534793Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.
Ref 526680J Med Chem. 2003 Jul 31;46(16):3514-25.A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
Ref 527412Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).
Ref 534791Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.